SU5416, a receptor tyrosine kinase inhibitor, is active in preclinical models of acute myeloid leukemia.

被引：0
|
作者：
Bertolini, F
Dell'Agnola, C
Gobbi, A
Monestiroli, S
Pruneri, G
McMahon, G
Martinelli, G
机构：
[1] European Inst Oncl, Milan, Italy
[2] Sugen Inc, San Francisco, CA USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
505
引用
收藏
页码：117A / 117A
页数：1
相关论文
共 50 条
  • [21] Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma
    Zangari, M
    Anaissie, E
    Stopeck, A
    Morimoto, A
    Tan, N
    Lancet, J
    Cooper, M
    Hannah, A
    Garcia-Manero, G
    Faderl, S
    Kantarjian, H
    Cherrington, J
    Albitar, M
    Giles, FJ
    CLINICAL CANCER RESEARCH, 2004, 10 (01) : 88 - 95
  • [22] A phase I/II study of SU5416, a tyrosine kinase inhibitor in patients with Von Hippel-Lindau syndrome.
    Madhusudan, S
    Cattell, E
    Price, P
    Tsolomas, M
    Moore, N
    Huson, S
    Adams, C
    Frith, P
    Scigalla, P
    Harris, AL
    BRITISH JOURNAL OF CANCER, 2002, 86 : S114 - S114
  • [23] SU5416, a VEGF Receptor Inhibitor and Ligand of the AHR, Represents a New Alternative for Immunomodulation
    Mezrich, Joshua D.
    Nguyen, Linh P.
    Kennedy, Greg
    Nukaya, Manabu
    Fechner, John H.
    Zhang, Xiaoji
    Xing, Yongna
    Bradfield, Christopher A.
    PLOS ONE, 2012, 7 (09):
  • [24] Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416
    Loges, Sonja
    Tinnefeld, Heike
    Metzner, Anja
    Juecker, Manfred
    Butzal, Martin
    Bruweleit, Melanie
    Fischer, Uta
    Draab, Elena
    Schuch, Gunter
    O'-Farrel, Anne Marie
    Hossfeld, Dieter Kurt
    Bokemeyer, Carsten
    Fiedler, Walter
    LEUKEMIA & LYMPHOMA, 2006, 47 (12) : 2601 - 2609
  • [25] A phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma
    Hoff, PM
    Wolff, RA
    Bogaard, K
    Waldrum, S
    Abbruzzese, JL
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (02) : 100 - 103
  • [26] Targeting receptor tyrosine kinase signaling in acute myeloid leukemia
    Doepfner, Kathrin T.
    Boller, Danielle
    Arcaro, Alexandre
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 63 (03) : 215 - 230
  • [27] Efficacy of AMG 176 in combination with gilteritinib in preclinical models of acute myeloid leukemia.
    Chen, Xiaoyue
    Caenepeel, Sean
    Belmontes, Brian
    McElroy, Patricia L.
    Rex, Karen
    Osgood, Tao
    Hughes, Paul
    CANCER RESEARCH, 2021, 81 (13)
  • [28] Phase II study of SU5416 - a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases
    Giles, FJ
    Cooper, MA
    Silverman, L
    Karp, JE
    Lancet, JE
    Zangari, M
    Shami, PJ
    Khan, KD
    Hannah, AL
    Cherrington, JM
    Thomas, DA
    Garcia-Manero, G
    Albitar, M
    Kantarjian, HM
    Stopeck, AT
    CANCER, 2003, 97 (08) : 1920 - 1928
  • [29] MLN8237, A NOVEL ORALLY ACTIVE AURORA A KINASE INHIBITOR, IS HIGHLY ACTIVE ALONE AND IN COMBINATION WITH CYTARABINE IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA
    Kelly, R.
    Swords, R.
    Mahalingam, D.
    Nawrocki, S.
    Medina, E.
    Smith, S.
    Padmanabhan, S.
    Ecsedy, J.
    Giles, F.
    Carew, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 339 - 340
  • [30] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Druker, BJ
    Talpaz, M
    Resta, DJ
    Peng, B
    Buchdunger, E
    Ford, JM
    Lydon, NB
    Kantarjian, H
    Capdeville, R
    Ohno-Jones, S
    Sawyers, CL
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14): : 1031 - 1037
12345